asciminib
novartis
['cml', 'asciminib']
#ash22 #cml 1st line asciminib in cml-cp (ascend trial): mmr 47% in 3 mo. well tolerated. 
Assistant Professor @MayoCancerCare @MayoClinic Alumni @MDAndersonNews. Interest in Acute Leukemia and Chronic myeloid disorders. Views are my own